Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             29 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Aggressive mast cell leukemia/sarcoma with CD4 expression and hemophagocytosis Heimes Dillon, Anna L.

141 11 p. 1364
artikel
2 A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease van Halteren, Astrid G. S.

141 11 p. 1277-1292
artikel
3 Back Matter
141 11 p. 1368
artikel
4 Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor Schavgoulidze, Anaïs

141 11 p. 1308-1315
artikel
5 Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy Schnegg-Kaufmann, Annatina S.

141 11 p. 1316-1321
artikel
6 del(1p32), a powerful prognostic factor in myeloma
141 11 p. 1367
artikel
7 Del(1p32): prime time in (ultra) high-risk myeloma Khot, Amit

141 11 p. 1241-1243
artikel
8 Determining venous thromboembolism risk in patients with adult-type diffuse glioma Burdett, Kirsten Bell

141 11 p. 1322-1336
artikel
9 Diffuse myocardial fibrosis occurs in young patients with sickle cell anemia despite early disease-modifying therapy Morin, Cara E.

141 11 p. 1358-1362
artikel
10 Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma Flerlage, Jamie E.

141 11 p. 1293-1307
artikel
11 Editorial Board
141 11 p. vi
artikel
12 Good or bad cops: immune cells in aGVHD Stary, Georg

141 11 p. 1238-1240
artikel
13 GVHD prophylaxis: use an ortho IL-2/IL-2Rβ Treg system! Wolf, Dietlinde

141 11 p. 1246-1247
artikel
14 Heart failure in SCA: still challenging Hammoudi, Nadjib

141 11 p. 1248-1249
artikel
15 How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL Myers, Regina M.

141 11 p. 1251-1264
artikel
16 Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. Blood. 2021;138(5):361-369.
141 11 p. 1366
artikel
17 Low-grade follicular lymphoma with extensive marginal zone differentiation and expression of MUM1 and CD30 Baykara, Yigit

141 11 p. 1363
artikel
18 Masthead Subscription
141 11 p. i
artikel
19 MDM2 and BCL-2: to p53 or not to p53? Wang, Eunice S.

141 11 p. 1237-1238
artikel
20 Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo Ramos, Teresa L.

141 11 p. 1337-1352
artikel
21 Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL Simonin, Mathieu

141 11 p. 1353-1358
artikel
22 Steffin DHM, Muhsen IN, Hill LC, et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022;140(1):16-24.
141 11 p. 1366
artikel
23 Summiting thrombotic hazards in glioma Goshua, George

141 11 p. 1245-1246
artikel
24 Table of Contents
141 11 p. iii-v
artikel
25 Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018;132(4):405-412.
141 11 p. 1365
artikel
26 The kids are alright: MDS clones mature Rao, Sridhar

141 11 p. 1243-1245
artikel
27 Unraveling family ties in Hodgkin lymphoma Fox, Lucy C.

141 11 p. 1240-1241
artikel
28 Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140(8):828-838.
141 11 p. 1366
artikel
29 Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial Daver, Naval G.

141 11 p. 1265-1276
artikel
                             29 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland